Bristol Myers' lung disease and cancer drugs succeed in late-stage trials

Bristol Myers Squibb $BMY announced positive results from Phase 3 trials for two drug candidates targeting lung disease and cancer, boosting investor confidence in its pipeline and lifting the stock in early trading.

The readout underscores the company's progress in expanding its therapeutic arsenal across oncology and respiratory conditions, key focus areas for pharma development.